Baxter (NYSE:BAX) announced today that the FDA granted 510(k) clearance for its Novum IQ large-volume infusion pump (LVP) with Dose IQ safety software.
Clearance adds the LVP to the Novum IQ platform, which already includes the Baxter syringe infusion pump (SYR). It enables clinicians to utilize a single, integrated system across a variety of patient care settings. The integrated user experience helps to reduce the burden of non-critical tasks, allowing for more focus on patient care.
Baxter said its new platform offers a common user interface with a digital, on-screen barcode. It streamlines training and reduces the cognitive burden associated with operating multiple, disparate pump platforms.
The system’s Dose IQ safety software features a web-based, customizable drug library and dose error reduction system. It supports clinicians and hospitals by ensuring that pumps remain up-to-date with the latest facility-specific drug and dosage parameters and information through centralized access to drug library files. Dose IQ also has exclusive titration error prevention technology.
Baxter also included its IQ Enterprise connectivity suite. It enables EMR interoperability, continuous quality improvement and over-the-air software updates.
The company said it made its Novum IQ system available to order in the U.S.
Heather Knight, EVP and group president, Medical Products and Therapies at Baxter, said: “Our goal, always, is to bring increased efficiency, safety and opportunity for informed decision-making to our customers, clinicians and the patients they serve. The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care. Offering Novum IQ large volume and syringe infusion pumps unlocks the potential of advanced, intuitive technologies that customers seek to meet their needs.”
